Marker Systems Based on MicroRNA Gene Methylation for the Diagnosis of Stage I-II Breast Cancer


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Groups of microRNA genes, methylation of which is associated with the initial (I-II) stages of breast cancer, are determined, and new markers and marker systems for the disease diagnosis were created on the basis of these data. A total of 14 genes in which methylation was associated with breast cancer were identified with the use of methyl-specific PCR on a representative sample of 70 tumor specimens. Analysis of 46 specimens from patients with clinical stages I and II detected 9 genes (MIR-124-1, MIR-124-3, MIR-125b-1, MIR-129-2, MIR-132, MIR-148a, MIR-193a, MIR-34b/c, and MIR-9-3), in which methylation was associated with the initial stages of the disease. Using ROC analysis, we formed two systems including 6 markers each and detecting breast cancer at stages I-II with high sensitivity (89 and 91%) and specificity (88%) at AUC=0.92-0.93. These sets were validated on the total sample of 70 specimens including all disease stages; they showed 93 and 94% sensitivities, 88% specificity, and AUC=0.95. Highly sensitive systems of markers, based on microRNA gene methylation, were created for the diagnosis of breast cancer at stages I-II.

About the authors

E. A. Braga

Research Institute of General Pathology and Pathophysiology; Medical Genetic Research Center

Author for correspondence.
Email: eleonora10_45@mail.ru
Russian Federation, Moscow; Moscow

E. A. Filippova

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

V. I. Loginov

Research Institute of General Pathology and Pathophysiology; Medical Genetic Research Center

Email: eleonora10_45@mail.ru
Russian Federation, Moscow; Moscow

I. V. Pronina

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

A. M. Burdennyi

Research Institute of General Pathology and Pathophysiology

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

T. P. Kazubskaya

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

M. V. Fridman

N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

D. S. Khodyrev

Federal Research Clinical Center of Specialized Types of Medical Care and Medical Technologies, Federal Biomedical Agency of Russia

Email: eleonora10_45@mail.ru
Russian Federation, Moscow

N. E. Kushlinskii

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: eleonora10_45@mail.ru
Russian Federation, Moscow


Copyright (c) 2019 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies